MedTrace Logo

Communication Bridge 3 Study

NCT06191198 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-05-30

No results posted yet for this study

Summary

This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.

Conditions

  • Primary Progressive Aphasia

Interventions

BEHAVIORAL

Communication Bridge™

Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.

BEHAVIORAL

Evidence-Based Impairment Focused

Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.

Sponsors & Collaborators

  • Western University, Canada

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Emily Roglaski, PhD · Professor of Neurology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-23
Primary Completion
2028-07-15
Completion
2028-07-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06191198 on ClinicalTrials.gov